Can Ficicioglu
Clinical Genetics (M.D.) · Philadelphia, PANPI 1114949617
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Sanofi at 38.6% of the total. Among clinical genetics (m.d.) clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 386 payments — averaging $946.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$141K
- Travere Therapeutics, Inc.$57K
- Amgen$40K
- Chiesi USA, Inc.$27K
- Takeda Pharmaceuticals U.S.A., Inc.$25K
- Shire North American Group Inc$16K
- plus $60K from 19 others
Across 936 payments — averaging $9538.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$4.2M
- Modernatx, Inc.$2.4M
- Takeda Pharmaceuticals U.S.A., Inc.$1.4M
- Zevra Therapeutics Inc$222K
- Shire North American Group Inc$141K
- Biomarin Pharmaceutical Inc.$135K
- plus $461K from 8 others
What the payments were for
- Consulting fees$186,24651%
- Speaking & faculty fees$88,11624%
- Travel & lodging$77,46221%
- Food & beverage$10,1183%
- Education$3,2571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 131 | $140,902 |
| Travere Therapeutics, Inc. | 35 | $56,941 |
| Amgen(2 entities) | 45 | $40,339 |
| Chiesi USA, Inc. | 14 | $26,613 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $24,505 |
| Shire North American Group Inc | 26 | $15,698 |
| Modernatx, Inc. | 40 | $12,871 |
| Biomarin Pharmaceutical Inc. | 14 | $11,993 |
| PTC Therapeutics, Inc. | 26 | $10,191 |
| Swedish Orphan Biovitrum AB | 3 | $9,212 |
| Ultragenyx Pharmaceutical Inc. | 1 | $3,200 |
| Amicus Therapeutics, Inc. | 1 | $2,768 |
| Cycle Pharmaceuticals Inc | 1 | $1,600 |
| NS Pharma, Inc. | 1 | $1,350 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,300 |
| GSK | 1 | $1,000 |
| Sanofi-aventis U.S. LLC | 1 | $900 |
| ZOLL Medical Corporation | 1 | $775 |
| Recordati_rare_diseases_inc. | 1 | $720 |
| Novo Nordisk | 1 | $600 |
| Dr.reddy's Laboratories,inc. | 1 | $600 |
| BTG International Inc. | 1 | $500 |
| Vertex | 1 | $392 |
| Intrabio Inc | 3 | $158 |
| Sobi, Inc | 1 | $71 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RAVICTI$39,410
- LAMZEDE$23,715
- VPRIV$21,788
- DISEASE STATE$15,907
- NO PRODUCT DISCUSSED$9,627
- Orfadin$9,212
- LUMIZYME$6,165
- CERDELGA$5,863
- Palynziq$5,507
- ELAPRASE$3,645
- DOJOLVI$3,200
- Naglazyme$2,938
- Vimizim$2,833
- POMBILITI$2,768
- OPFOLDA$2,768
- XENPOZYME$2,303
- FABRAZYME$1,884
- Nityr$1,600
- ALDURAZYME$900
- Defibrillator$775
How this compares
$365,199 in reported general payments places this provider in the 95th percentile of 26 clinical genetics (m.d.) providers in Pennsylvania.
See all clinical genetics (m.d.) providers in Pennsylvania →
Other clinical genetics (m.d.) in Philadelphia
- Staci KallishPhiladelphia$189K
- Jennifer KalishPhiladelphia$37K
- Paige KaplanPhiladelphia$21K
- Georgianne ArnoldPhiladelphia$16K
- Neal SondheimerPhiladelphia$13K
- Alanna StrongPhiladelphia$6K
- Tarachandra NarumanchiPhiladelphia$6K
- Katherine NathansonPhiladelphia$5K
- Reena JethvaPhiladelphia$3K
- Marni FalkPhiladelphia$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.